NASDAQ:SKYE Skye Bioscience (SKYE) Stock Price, News & Analysis $5.22 +0.07 (+1.36%) (As of 10/29/2024 09:05 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Skye Bioscience Stock (NASDAQ:SKYE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$4.90▼$5.2250-Day Range$3.55▼$5.2252-Week Range$1.44▼$19.41Volume176,700 shsAverage Volume179,561 shsMarket Capitalization$158.36 millionP/E RatioN/ADividend YieldN/APrice Target$18.67Consensus RatingBuy Company OverviewSkye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.Read More… Banking failure dead ahead (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Skye Bioscience Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks33rd Percentile Overall ScoreSKYE MarketRank™: Skye Bioscience scored higher than 33% of companies evaluated by MarketBeat, and ranked 825th out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingSkye Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSkye Bioscience has only been the subject of 4 research reports in the past 90 days.Read more about Skye Bioscience's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Skye Bioscience are expected to decrease in the coming year, from ($1.06) to ($1.21) per share.Read more about Skye Bioscience's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.77% of the float of Skye Bioscience has been sold short.Short Interest Ratio / Days to CoverSkye Bioscience has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Skye Bioscience has recently increased by 17.36%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSkye Bioscience does not currently pay a dividend.Dividend GrowthSkye Bioscience does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.77% of the float of Skye Bioscience has been sold short.Short Interest Ratio / Days to CoverSkye Bioscience has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Skye Bioscience has recently increased by 17.36%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.56 News SentimentSkye Bioscience has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Skye Bioscience this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for SKYE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows13 people have added Skye Bioscience to their MarketBeat watchlist in the last 30 days. This is an increase of 333% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Skye Bioscience insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,750,352.00 in company stock.Percentage Held by InsidersOnly 3.00% of the stock of Skye Bioscience is held by insiders.Percentage Held by InstitutionsOnly 21.09% of the stock of Skye Bioscience is held by institutions.Read more about Skye Bioscience's insider trading history. SKYE Stock News HeadlinesMarketBeat Week in Review – 10/7 - 10/11 (SKYE)Stocks delivered another winning week, but the latest inflation readings dampened hopes for aggressive rate cuts and turned attention toward earningsOctober 12, 2024 | marketbeat.comDon’t Sleep on Skye Bioscience—This Weight Loss Drug Could SoarSkye Bioscience has incredible potential upside, according to Wall Street analysts. It is striving to make a new weight loss drug, that could work with GLP-1s.October 9, 2024 | marketbeat.comKickstart your own Weekend Side Hustle right from your couch Today I want to show you how to start your very own Weekend Side Hustle right from the comfort of your sofa! It doesn't matter if you have a multi-million dollar retirement account… Or if you’re just starting out with a few thousand.October 30, 2024 | DTI (Ad)3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't IgnoreCheck out these three micro-cap companies that have a big opportunity to succeed, but also significant a risk of failure.October 4, 2024 | marketbeat.comSkye Bioscience, Inc. (NASDAQ:SKYE) Receives $18.67 Average Target Price from BrokeragesOctober 30 at 1:51 AM | americanbankingnews.comSkye Bioscience names Grayson as Chairman of the BoardOctober 29 at 6:39 PM | markets.businessinsider.comSkye Bioscience Names Independent Director Paul Grayson as Chairman of the BoardOctober 29 at 6:39 PM | markets.businessinsider.comSkye Bioscience Approves Incentive Plan Amendments and Leadership ChangesOctober 25, 2024 | markets.businessinsider.comSee More Headlines SKYE Stock Analysis - Frequently Asked Questions How have SKYE shares performed this year? Skye Bioscience's stock was trading at $2.72 on January 1st, 2024. Since then, SKYE stock has increased by 91.9% and is now trading at $5.22. View the best growth stocks for 2024 here. How were Skye Bioscience's earnings last quarter? Skye Bioscience, Inc. (NASDAQ:SKYE) announced its earnings results on Friday, August, 9th. The company reported ($0.20) earnings per share for the quarter, hitting the consensus estimate of ($0.20). How do I buy shares of Skye Bioscience? Shares of SKYE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Skye Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Skye Bioscience investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Alphabet (GOOG). Company Calendar Last Earnings8/09/2024Today10/29/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SKYE Previous SymbolNASDAQ:SKYE CUSIPN/A CIK1516551 Webskyebioscience.com Phone858-410-0266FaxN/AEmployees11Year FoundedN/APrice Target and Rating Average Stock Price Target$18.67 High Stock Price Target$25.00 Low Stock Price Target$14.00 Potential Upside/Downside+257.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,650,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-111.83% Return on Assets-80.69% Debt Debt-to-Equity RatioN/A Current Ratio6.07 Quick Ratio6.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.17) per share Price / Book-30.71Miscellaneous Outstanding Shares30,338,000Free Float29,428,000Market Cap$158.36 million OptionableOptionable Beta1.78 This page (NASDAQ:SKYE) was last updated on 10/30/2024 by MarketBeat.com Staff From Our Partners625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredThe most serious warning of my careerWith the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the ...Porter & Company | SponsoredThis biotech's ONE drug could change medicine as we know itThis Clinical-stage Biotech Company is Taking a Revolutionary Approach to Eradicating Many Respiratory Viruses...Smallcaps Daily | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThe Death Knell for U.S. StocksThey are among the 31 billionaires dumping their stocks at a record pace. Fortune calls this phenomenon "Th...InvestorPlace | SponsoredInvest in the company that won over the DragonsThe pioneer in smart-doorbell technology, RING, pitched their business on the hit show Shark Tank at a valuati...RYSE | SponsoredA Gold Storm Is ComingStrange new catalyst for gold ($5,000 possible?) Many are wondering why so many countries are frantically b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Skye Bioscience, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Skye Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.